CD274 and esophageal squamous cell carcinoma: The KEYNOTE-590 trial demonstrated that pembrolizumab plus chemotherapy in ESCC patients with a PD-L1 CPS ≥10 improved median OS to 13.9 months compared to 8.8 months with chemotherapy alone (HR 0.62, P<0.001) [13].